NASDAQ:AMED
Amedisys Inc Stock News
$91.16
-0.0800 (-0.0877%)
At Close: Apr 23, 2024
Amedisys to Present at Multiple Healthcare Conferences in June
08:00am, Wednesday, 25'th May 2022
BATON ROUGE, La., May 25, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard, Pre
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
02:07pm, Wednesday, 11'th May 2022 Zacks Investment Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
11:17am, Wednesday, 11'th May 2022
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Amedisys Celebrates National Nurses Week
10:30am, Friday, 06'th May 2022 GlobeNewswire Inc.
BATON ROUGE, La., May 06, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care, palliative and high-acuity care, celebrates National Nurs
7 Analysts Have This to Say About Amedisys
01:24pm, Friday, 29'th Apr 2022 Benzinga
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
3
0
0
Last 3
Amedisys to Present at Multiple Healthcare Conferences in May
12:00pm, Friday, 29'th Apr 2022 GlobeNewswire Inc.
BATON ROUGE, La., April 29, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard,
Amedisys to Present at Multiple Healthcare Conferences in May
08:00am, Friday, 29'th Apr 2022
BATON ROUGE, La., April 29, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard, P
Amedisys, Inc. (AMED) CEO Christopher Gerard on Q1 2022 Results - Earnings Call Transcript
05:45pm, Thursday, 28'th Apr 2022
Amedisys, Inc. (NASDAQ:AMED ) Q1 2022 Earnings Conference Call April 28, 2022 11:00 AM ET Company Participants Nick Muscato - Chief Strategy Officer Christopher Gerard - CEO, President & Director Scot
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
02:31pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
12:04pm, Thursday, 28'th Apr 2022
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Amedisys (AMED) Q1 Earnings Top Estimates
09:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
08:05pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
BATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022.
Amedisys Announces First Quarter 2022 Earnings Release and Conference Call Date
12:00pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
BATON ROUGE, La., April 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for th
Amedisys Announces First Quarter 2022 Earnings Release and Conference Call Date
08:00am, Wednesday, 13'th Apr 2022
BATON ROUGE, La., April 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the
Here's Why You Should Retain Amedisys (AMED) Stock For Now
02:11pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
